An Australian multicentre open label study of pergolide as an adjunct to levodopa in Parkinson's disease

Journal of Clinical Neuroscience

Volumn 3, Issue 3, 1996, Pages 234-238

  Hely, M A ^a   Morris, J G L ^a   Burns, R J ^b   Lander, C M ^c   McLaughlin, D B ^c   Donnan, G A ^d  

^a WESTMEAD HOSPITAL   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d AUSTIN HOSPITAL   (Australia)

Author keywords

Levodopa; Parkinson's disease; Pergolide; Therapy

Indexed keywords

EID: 0000104294     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0967-5868(96)90056-9     Document Type: Article

References (20)

1. Lemberger L, Crabtree RE. Pharmacologic effects in man of a potent long-acting dopamine receptor agonist. Science 1979; 205: 1151-1153.
2. Goldstein M, Lieberman A, Lew JY et al. Interaction of pergolide with central dopaminergic receptors. Proc Natl Acad Sci USA 1980; 77: 3725-3728.
3. Rubin A, Lemberger L, Dhahir P. Physiologic disposition of pergolide. Clin Pharmacol Ther 1981; 30: 258-265.
4. Koller WC, Weiner WJ, Diamond BI, Nausieda PA, Klawans HL. The pharmacological evaluation of pergolide mesylate as a potential anti-Parkinsonian agent. Neuropharmacology 1980; 19: 831-837.
5. Tanner CM, Goetz CG, Glantz RH, Glatt SL, Klawans HL. Pergolide mesylate and idiopathic Parkinson disease. Neurology 1982; 32: 1175-1179.
6. Lang AE, Quinn N, Brincat S, Marsden CD, Parkes JD. Pergolide in late-stage Parkinson disease. Ann Neurol 1982; 12: 243-247.
7. Lieberman AN, Leibowitz M, Neophytides A, et al. Pergolide and lisuride for Parkinson's disease. Lancet 1979; 2: 1129-1130.
8. Jankovic J. Long-term study of pergolide in Parkinson's disease. Neurology 1985; 35: 296-299.
9. Olanow CW, Fahn S, Muenter M et al. A multicentre double- blind, placebo-controlled trial of pergolide as as adjunct to sinemet in Parkinson's disease. Mov Disord 1994; 9: 40-47.
10. LeWitt PA, Ward CD, Larsen TA et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983; 33: 1009-1014.
11. Pezzoli G, Martignoni E, Pacchetti C et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. Neurology 1995; 45: (suppl 3): S22-S27.
12. Lieberman AN, Neophytides A, Leibowitz M et al. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Adv Neurol 1983; 37: 95-108.
13. Goetz CG, Tanner CM, Glantz RH, Klawans HL. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology 1985; 35: 749-751.
14. Factor SA, Sanchez-Ramos JR, Weiner WJ. Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy. J Neurol Neurosurg Psych 1988; 51: 529-533.
15. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
16. Chen R-C. Abbreviated rating score for Parkinson's disease. Chin Med J (Taipei) 1991; 47: 71-78
17. Diamond SG, Markham CH, Treciokas LJ. Double-blind trial of pergolide for Parkinson's disease. Neurology 1985; 35: 291-295
18. Carlson JH, Bergstrom DA, Walters JR. Stimulation of both D1 and D9 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: a neurophysiological study. Brain Res 1987; 400: 205-218.
19. Olanow CW. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 1992; 32: S2-S9.
20. Hely MA, Morris JGL, Reid WGJ et al. The Sydney multicentre study of Parkinson's disease: a randomised, prospective 5 year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psych 1994; 57: 903-910.